Study of anxiolytic activity and possible side effects of the dipeptide ligand of the translocator protein TSPO — compound GD-102 in a wide range of doses in behavioral experiments using rats and mice

Background. The dipeptide TSPO ligand, the compound amide N-phenylpropionyl-L-tryptophanyl-L-leucine (GD-102) was designed and synthesized in the Federal research center for innovator and emerging biomedical and pharmaceutical technologies. It was shown that GD-102 possessed anxiolytic and antidepressant-like activity in behavioral experiments using mice.

The aim of this work was studying the anxiolytic activity and possible side effects of GD-102 in a wide range of doses from 0.01 to 5.0 mg/kg in experiments using rats and mice.

Materials and methods. The pharmacological effects of GD-102 were studied with single intraperitoneal administration. The anxiolytic activity of GD-102 was studied in rats in the elevated plus maze test. The "climbing on the net" test was used to record orientation-exploratory behavior; the muscle relaxant properties were studied in the "rotating rod" and "horizontal bar" tests.

Results. It was found that GD-102 at doses of 1.0 and 0.1 mg/kg (once administration), has a pronounced anxiolytic effect in the elevated plus maze test, significantly increasing the time the rats spent in the open arms of the maze and the number of entries into the open arms of the maze. The study of the sedative/activating effects on various behavior models indicated that GD-102 in a wide range of doses (from 0.01 to 5.0 mg/kg) did not affect orientation-exploratory behavior. In the dose range from 0.01 to 5.0 mg/kg, compound GD-102 does not impair the coordination of movements in the rotating rod test and the pull-up reflex on a horizontal bar, which indicates that compound GD-102 have not side effect on muscle relaxantion.

Conclusion. The obtained results allow us to conclude that the dipeptide ligand of the TSPO translocator protein, compound GD-102, has a pronounced anxiolytic effect and does not have a sedative or muscle relaxant effect in a wide range of doses, which determines the feasibility of its further expanded preclinical study.

1. Aleksandrovsky YuA. Pre-morbid conditions and borderline mental disorders (etiology, pathogenesis, specific and nonspecific symptoms, therapy). Moscow: Litterra; 2010. (In Russ.). ISBN 978-5-904090-28-9.

2. Neznanov NG, Martynikhin IA, Mosolov SN. Diagnosis and treatment of Anxiety Disorders in Russia: The Results of a Web-based Survey of Psychiatrists. Current Therapy of Mental Disorders. 2017;2:2-13. (In Russ.). doi: 10.21265/PSYPH.2017.41.6437.

3. Grigorova OV, Akhapkin RV, Aleksandrovskiĭ IuA. Modern concepts of pathogenetic therapy of anxiety disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10):111-120. (In Russ.). doi: 10.17116/jnevro2019119101111.

4. Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 Sep;21(9):655-79. doi: 10.1016/j.euroneuro.2011.07.018.

5. Sansone RA, Sansone LA. Psychiatric disorders: a global look at facts and figures. Psychiatry (Edgmont). 2010 Dec;7(12):16-9.

6. Bahi A, Al Mansouri S, Al Memari E, et al. β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice. Physiol Behav. 2014 Aug;135:119-24. doi: 10.1016/j.physbeh.2014.06.003.

7. Kandola A, Lewis G, Osborn DPJ, et al. Depressive symptoms and objectively measured physical activity and sedentary behaviour throughout adolescence: a prospective cohort study. Lancet Psychiatry. 2020 Mar;7(3):262-271. doi: 10.1016/S2215-0366(20)30034-1.

8. Baxter AJ, Scott KM, Ferrari AJ, et al. Challenging the myth of an "epidemic" of common mental disorders: trends in the global prevalence of anxiety and depression between 1990 and 2010. Depress Anxiety. 2014 Jun;31(6):506-16. doi: 10.1002/da.22230.

9. Mokrov GV, Deeva OA, Yarkova MA, et al. Translocator protein TSPO 18 kDa and its ligands: a promising approach to the creation of new neuropsychotropic drugs. Farmakokinetika i farmakodinamika = Pharmacokinetics and pharmacodynamics. 2018;(4):3-27. (In Russ.). doi: 10.24411/2588-0519-2018-10026.

10. Deeva OA, Pantileev AS, Rybina IV, et al. A Novel Dipeptide Ligand of TSPO. Dokl Biochem Biophys. 2019 May;484(1):17-20. doi: 10.1134/S1607672919010046.

11. Gudasheva TA, Deeva OA, Pantileev AS, et al. The New Dipeptide TSPO Ligands: Design, Synthesis and Structure-Anxiolytic Activity Relationship. Molecules. 2020 Nov 4;25(21):5132. doi: 10.3390/molecules25215132.

12. Patent RU. № 2756772 06.12.2018. Dipeptide TSPO ligands with neuropsychotropic activity. (In Russ.). Доступно по: https://rusneb.ru/catalog/000224_000128_2018143150_20200608_A+_RU/?ysclid=m7uwe8foje535944644. Ссылка активна на 20.01.2025

13. Deeva OA, Yarkova MA, Mokrov GV, et al. Dipeptide ligands of TSPO. Pharmaceutical Chemistry Journal. 2022;56(9):1169-1178. (In Russ.). doi: 10.30906/0023-1134-2022-56-9-14-23.

14. Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 1985 Aug;14(3):149-67. doi: 10.1016/0165-0270(85)90031-7.

15. Voronina TA, Seredenin SB, Yarkova MA, Voronin MV. Methodological recommendations for the preclinical study of the tranquilizing (anxiolytic) effect of drugs. Guidelines for conducting preclinical studies of medicines. Part one. Moscow: Grif i K; 2012;264-275. (In Russ.).

16. Voronina TA, Ostrovskaya RU, Garibova TL. Methodological recommendations for the preclinical study of drugs with a nootropic type of action. Guidelines for conducting preclinical studies of medicines. Part one. Moscow: Grif i K; 2012:276-296. (In Russ.).